Screening for left ventricular systolic dysfunction in patients with stroke, transient ischaemic attacks, and peripheral vascular disease

Evaluation of training nurses to perform semi‐automated three‐dimensional left ventricular ejection fraction using a customised workstation‐based training protocol

“…There are a number of clinical applications for nurse-led, 3D-LVEF quantification. First, this opens the way for population screening for LVSD in high-risk cohorts (Galasko et al 2006), particularly in a clinic setting, such as diabetes, hypertension and vascular clinics (Kelly & Struthers 1999). This would represent a paradigm shift to allow early detection and management of asymptomatic LVSD with the potential to prevent heart failure and improve long-term survival (Ammar et al 2007, Atherton 2012.…”

“…vascular disease, obesity, hypertension, diabetes) with these patients having a higher prevalence of left ventricular (LV) systolic dysfunction (LVSD) (Atherton , Gardin et al . , Kelly & Struthers , Wilson ). Importantly, there are a number of treatments that have been shown to reduce the risk of death and development of HF in asymptomatic LVSD (Hunt et al .…”

“…There are a number of well-recognised HF risk factors (e.g. vascular disease, obesity, hypertension, diabetes) with these patients having a higher prevalence of left ventricular (LV) systolic dysfunction (LVSD) (Atherton 2010, Gardin et al 1995, Kelly & Struthers 1999, Wilson 1997. Importantly, there are a number of treatments that have been shown to reduce the risk of death and development of HF in asymptomatic LVSD (Hunt et al 2005, Atherton 2012), however we need to identify these patients before we can treat them (Frigerio et al 2003).…”

Screening for Left Ventricular Systolic Dysfunction: Is Imaging a Solution?

“…Men are 2 to 3 times more likely to be affected with a strong age predilection. In selected high-risk groups such as patients with vascular disease or diabetes mellitus, up to 20% may have LVSD (11).…”

Annual Scientific Meeting of ASCEPT, 1999 Careful Screening To Target Interventions To Prevent Sudden Cardiac Death

“…In an as yet unpublished recent study, we found that 28% of patients who first present with peripheral vascular disease or cerebrovascular disease had a reduced LVEF (< 40%). This is in itself interesting because it is traditionally assumed that patients with peripheral vascular disease (PVD), TIA and CVA have a high incidence of cardiac death because they have fresh myocardial ischaemic/infarction events, but it may be possible that their death is ‘arrhythmic’ due to their low LVEF 3 . This is important because death due to a low LVEF can be reduced by pharmacological therapy (β‐adrenoceptor blockade, ACE inhibitor and spironolactone).…”